Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT). Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures. Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer. Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.
Awards & Honors
Recent Significant Publications
Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2013 Mar 5.
Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7.
Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34.
Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K, Hsu IC. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):222-7.
Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M 3rd, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21;56(24):7767-75.
Faddegon BA, Aubin M, Bani-Hashemi A, Gangadharan B, Gottschalk AR, Morin O, Sawkey D, Wu V, Yom SS. Comparison of patient megavoltage cone beam CT images acquired with an unflattened beam from a carbon target and a flattened treatment beam. Med Phys. 2010 Apr;37(4):1737-41.
Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M 3rd, Ma L. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):58-63.
Aubry JF, Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy. 2009 Oct-Dec;8(4):339-44.
Aubry JF, Cheung J, Morin O, Gottschalk A, Beaulieu L, Pouliot J. Correction of megavoltage cone-beam CT images of the pelvic region based on phantom measurements for dose calculation purposes. PMID 19223832 Journal of Applied Clinical Medical Physics 10(1):2852, 2009.
Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, and Shinohara K. Salvage permanent perineal radioactive seed implantation for the treatment of localized prostate adenocarcinoma recurrent after external beam radiation. PMID: 19245439 British Journal Urology International, February 23, 2009.
Cheung J, Aubry JF, Yom S, Gottschalk AR, Celi JC and Pouliot J. Dose recalculation and the dose-guided radiation therapy (DGRT) process using megavoltage cone-beam CT. PMID 19345518 International Journal of Radiation Oncology*Biology*Physics 74:583-92, 2009
Jabbari S, Weinberg VV, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, and Roach M. Equivalent Biochemical Control and Improved PSA Nadir Following Permanent Prostate Seed Implant Brachytherapy (PPI) Versus High-Dose Three Dimensional Conformal Radiotherapy (3DCRT) and High-Dose Conformal Proton Beam Radiotherapy Boost (CPBRTB). PMID 19409729. International Journal of Radiation Oncology*Biology*Physics April 29, 2009.
Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, McLaughlin Roach M 3rd, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. PMID 19428310. Brachytherapy May 8, 2009.
Wu V, Aubin M, Bani-Hashemi A, Gangadharan B, Gottschalk AR, Morin O, Yom SS, and Faddegon B. High quality low dose con beam CT images of patents with a megavoltage imaging beam line. In press. International Journal of Radiation Oncology*Biology*Physics, 2009
Burk TF, Horvai AE, Gottschalk AR, Leong SPL, Law J, and O’Donnell RJ. Pediatric Patellar metastatic melanoma: case report and literature review. In press. American Journal of Orthopedics. 2009
Chan L, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, and Roach M. Proposed rectal dose constraints for patients undergoing definitive whole-pelvis radiotherapy for clinically localized prostate cancer. International Journal of Radiation Oncology*Biology*Physics Mar 12, 2008.
Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, and Ma L. Simulated real time image guided intra-fraction tracking-delivery for hypofractionated prostate IMRT. Medical Physics 35: 4041-48, 2008.
Schiffner D, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, His IC, Siniohara K and Roach M. Daily Electronic Portal Imaging of Implanted Gold Seed Fiducials in Patients Undergoing Salvage Radiotherapy After Radical Prostatectomy. International Journal of Radiation Oncology* Biology * Physics 67(2): 610-619, 2007.
Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, and Hsu IC. Feasibility of High Dose Rate (HDR) Brachytherapy Salvage for Local Prostate Recurrence After Radiotherapy: The UCSF Experience. International Journal of Radiation Oncology*Biology*Physics 67(4): 1106-1112, 2007.
Morin O, Gillis A, Descovich M, Chen J, Aubin M, Aubry JF, Chen H, Gottschalk AR, Xia P and Pouliot J. Patient dose considerations for megavoltage Cone-Beam CT Imaging. Medical Physics 34(5): 1819-27, 2007.